LOTTE Biologics Strengthens Manufacturing Capacity with Songdo Plant Milestone

LOTTE Biologics announced that it has completed major construction and obtained approval for use for Plant 1 at its Songdo Bio Campus in Incheon, South Korea.

The milestone was achieved approximately two years after the start of construction in 2024, representing an exceptionally fast project execution timeline among global biologics manufacturing facility construction projects.

 The facility has also been designed to maximize the company's ability to provide customized support for customers during future commercial manufacturing.

Through its dual-site strategy linking Songdo Bio Campus with Syracuse Bio Campus in New York, the United States, LOTTE Biologics is now positioned to provide integrated CDMO services that connect early-stage clinical production with large-scale commercial manufacturing. Under this model, the Syracuse Bio Campus will support early-stage customer projects and clinical supply, while Songdo Plant 1 will serve as a large-scale commercial manufacturing base. This dual-site structure enables the company to respond flexibly to a broad range of customer needs, from small-scale projects to large commercial production volumes.

Based on its manufacturing network spanning the United States and Korea, LOTTE Biologics anticipates enhanced support for customers' regional supply strategies and growing demand for supply chain risk diversification.